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ABSTRACT 
Objective: The objective of this study was to formulate and evaluate liposomes loaded with acyclovir. 
Methods: Liposomal formulation of acyclovir was prepared by “thin lipid film method”. Mixture of phosphotidyl choline (soya lecithin), acyclovir 
and cholesterol of varying weight ratio was used for the preparation of liposomes. Total nine batches were prepared and each batch was prepared 
in triplicate. All batches were evaluated by drug entrapment and release kinetic studies. Stability study was carried out with F4 batch. 
Results: F2 and F9formulations showed better drug entrapment efficiency compared to the other batches. The drug entrapment efficiency of all 
batches was found within the range of 51.42 % to 79.0 %. F4 shows highest release of about 79.0% in 4 h. F4 formulation was found to follow 
significantly zero-order release kinetics. Short term stability study of formulation F4 showed no significant change in release kinetics. 
Conclusion: The F4 batches showed promising results compared to other formulations. No changes were founded during the short-term stability study of F4. 
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Liposomes are composed of a lipid bilayer which used as drug 
delivery vehicles. The hydrophobic chains of the lipids form the 
bilayer and the polar head groups of the lipids are towards the 
extra vesicular solution and inner cavity. Liposomes have polar 
and non-polar groups on the same molecule. Due to hydrophilic 
and lipophilic interactions they can form self-organized and 
ordered structures in solvents [1]. Liposomes can give ligand 
targeted, long-acting and triggered release systems. Liposome 
preparation techniques may be broadly classified into two types–
bulk method and film method. In bulk method phospholipids are 
transferred from an organic phase into an aqueous phase. In the 
film method lipid films are deposited on a substrate followed by 
hydration to get the liposomes. Liposomal preparations have also 
been classified according to mean size, polydispersity and 
lamellarity of liposomes [2]. The hydrophilic part of liposomes is 
mainly phosphoric acid bound to water-soluble molecules. On the 
other hand hydrophobic part of liposome contains two fatty acid 
chains with 10 to 24 carbon atoms and each chain contains 0 to 6 
double bonds [3]. 
Most antiviral agents which have activity against the herpes group 
of viruses belong to a class of compounds known as nucleosides. 
Acyclovir or 9-(2-hydroxyethoxy methyl) guanine is one of those 
antiviral agents [4]. Oral absorption of acyclovir is about 20% [5, 
6]. Serious infections must be treated with intravenous acyclovir. 
The drug distributes all over the body. Cerebrospinal fluid (CSF) 
concentration is less than half of plasma concentration. The drug is 
excreted unchanged through kidneys. Excretion can be by both 
glomerular filtration and tubular secretion. Acyclovir has a half-
life of about 2.5 to 3 h that can increase in renal impairment. Most 
importantly acyclovir used in encephalitis caused by herpes 
simplex, skin infections with herpes simplex, including labial and 
genital herpes can be treated by topically applied acyclovir [7, 8]. 
Acyclovir has different routes of administration like topical, oral 
and intravenous but it is discovered that intravenous formulation 
has most profound antiviral effect in case of in vivo study [9]. 
Intramuscular or subcutaneous administration of liposomal 
formulation in suspension form can increase the therapeutic 
efficacy of the encapsulated drug. When liposomal formulation 
was administered intramuscularly, toxicity of therapeutic drugs 
was found to be reduced [9-11]. Liposomes can be used as delivery 
vehicles for chemotherapeutics [12]. Human Immunodeficiency 
Virus (HIV)-infected persons have more risks of herpes-zoster 
than non-HIV patients. In those cases acyclovir can reduce 
incidence in HIV-infected persons [13]. 
MATERIALS AND METHODS 
Materials 
Acyclovir, Phosphatidyl Choline (soya lecithin), and cholesterol were 
purchased from Yarrow Chem, Mumbai. Chloroform was purchased 
from Merck, India. All the other chemicals and reagents used were of 
analytical grade. 
Preparation of liposomes 
For the preparation of acyclovir liposomes “Thin Lipid Film 
Method” was employed. A mixture of phosphatidylcholine (soya 
lecithin), acyclovir and cholesterol of specific ratio were 
dissolved in 5 ml of chloroform [14-16] with sonication for 10-
20 min. The organic solution was taken in a round bottom flask 
and rotated on a thermostatic water bath (30 °C-35 °C) to 
evaporate the organic solvent [17]. The drying process was 
continued for about 40 min. The mixture of lipid and drug was 
deposited as a thin film in the round-bottom flask after complete 
evaporation of chloroform [18]. Proper drying plays a very 
important role in the preparation of liposomes [19]. After 
drying, 5 ml phosphate buffer (pH 7.4) was added and sonication 
was applied until a milky white suspension was formed 
(temperature maintained at 35 °C). Liposomes were formed due 
to spontaneous hydration of lipids in aqueous media. The 
suspension was allowed to stand for overnight. Sonication for 1 
hour was applied to reduce the particle size [20]. 
Entrapment study 
Liposomal suspension, 1 ml was taken in a glass centrifuge tube, 
followed by centrifugation [21] at 3500 rpm for 40 min. The 
supernatant was completely removed by a micropipette followed by 
washing the pellet with 5 ml of phosphate buffer solution (pH 7.4) to 
remove any un-entrapped drug. Both of the solutions were pooled 
and the clear supernatant solution was diluted. The absorbance was 
measured in UV-spectrophotometer (ELICO SA165) at 253 nm 
against phosphate buffer (pH 7.4) as blank. 
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In vitro drug release study 
The drug release study of acyclovir from different liposomal 
formulations was carried out by diffusion technique [22]. Liposomal 
acyclovir suspension, 5 ml was taken in a dialysis bag [Abron Visking 
tube BE-253-b] [23, 24]. Both ends of the bag were clipped. The bag 
was immersed in a medium of phosphate buffer (pH 7.4). The 
medium was maintained at 37± 0.2 °C with constant stirring by a 
magnetic stirrer. Aliquots of samples (2 ml) of the medium were 
withdrawn at every 15 min interval up to 4 h. The volume of the 
medium was made up with 2 ml pre-warmed phosphate buffer (pH 
7.4) [22, 23] after each sampling. The concentration of the sample 
was determined by taking the absorbance in UV-spectrophotometer 
(Elico SA165) at 253 nm against phosphate buffer (pH 7.4) as blank. 
Drug stability study 
Freshly prepared liposomal formulation of acyclovir that gave a 
better-sustained release pattern was stored in Eppendrof’s tube at 4 
°C [25] for one month. At the end of 1 mo, samples were analyzed by 
drug release study. 
RESULTS 
Drug entrapment efficiency 
The un-entrapped drug was extracted out from the liposomal 
suspension with the help of phosphate buffer (pH 7.4) and the 
amount of un-entrapped drug was determined. The amount of drug 
entrapped was determined by subtracting from the amount of drug 
taken initially. Entrapment efficiency was determined from the 
following equation [26]: 





 X 100 
The Drug Entrapment Efficiency (%) values found with various 
cholesterol proportions (mol %) are shown in fig. 1. 
  
 
Fig. 1: Drug entrapment efficiency (%) versus mol % of the cholesterol in total lipid. (N=3, Mean ± SD) 
 
From fig. 1 it is evident that % entrapment increases with a decrease 
in mol % of the cholesterol in the liposome and it became lowest at 
39.5 mol% cholesterol (F3), the lowest entrapment efficiency being 
51.42%. The highest entrapment efficiency (73.6%) was found with 
F9 having cholesterol of 17.9 mol%. 
In vitro drug release study from liposomes 
The dissolved acyclovir was diffused from liposome to the 
suspending medium and then permeated [27] across the dialysis 
membrane. Passage of the drug across dialysis membrane is a 
passive process. Therefore the rate of permeation was assumed to 
be higher than the rate of release of acyclovir from the liposome in 
the suspending medium. The percentage of drug released from the 
liposome was plotted against time and the release profiles of all the 
liposomal formulations are plotted in fig. 2. F4 shows highest release 
of about 79.0% in 4 h. 
Determination of t30 (Time required for 30 % drug release) 
In order to compare between the release profiles of various 
formulations a parameter, time required for 30% release (t30), was 
determined. The release rate was found to be highest in F4 
containing 32.9 mol% of cholesterol in the lipid phase which is 
exhibited by the lowest t30 value in fig. 3. The corresponding t30 value 
of F4 was found to be 97.5 min. 
 
 
Fig. 2: Drug release study of F1, F2, F3, F4, F5, F6, F7, F8 and F9 
Das et al. 




Fig. 3: Time taken for 30% release of drug from all formulations, (N=3, Mean ± SD) 
 
In vitro drug release kinetic modeling 
The dissolved acyclovir was diffused from liposome to the 
suspending medium and then permeated [27] across the dialysis 
membrane. Passage of the drug across dialysis membrane is a 
passive process. Therefore the rate of permeation was assumed to 
be higher than the rate of release of acyclovir from the liposome in 
the suspending medium. In order to model the release kinetics of 
various liposomal formulations, the release profiles of drug from the 
liposomes were fitted to Zero-order, First-order, Higuchi, Hixon-
Crowell, and Korsmeyer-Peppasequations. The correlation 
coefficients obtained from each model is displayed in table 1. 
 
Table 1: Determination of coefficient of correlations of various kinetic models 



























































































The mean values from 27 formulations (9 formulations x triplicate) are plotted against various kinetics models for comparison (vide fig. 4). From 
fig. 4 it is evident that the highest R2 value was found with Zero-order release kinetics. 
 
 
Fig. 4: The correlation coefficient values (R2) obtained from different kinetic models, (Mean ±SD, n = 27) 
Das et al. 
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The mean R2 values of Zero-order, First-order and Hixon-Crowell 
models were found to be close to each other. Hence, two-sample t-
tests between (i) Zero-order and First-order and (ii) Zero-order and 
Hixon-Crowell models were carried out with Minitab 18 software. In 
both cases, the difference between two means was found to be 
significant at 95% confidence level. Therefore, the R2–value of Zero-
order kinetics was found to be significantly highest among Zero, 
First and Hixon models. Therefore, it may be concluded that the 
release of acyclovir from the liposomes may be assumed to follow 
zero-order kinetics. 
 
Drug stability study 
Table 2: Drug stability study 
Time Batch Color Percentage of drug entrapment efficiency t30 (min) Changes in physical properties 
1 mo F4 Yellow  62.38±5.24 101.44±7.65 No changes  
(N=3, Mean ± SD) 
 
Formulation F4 was stored in three Eppendorf’s tubes for one 
month. At the end of one month, samples were analyzed and the 
results are displayed in table-2. The values of drug entrapment 
efficiency and t30 were found to be altered insignificantly. Therefore, 
the liposomes may be assumed to be stable till one month. 
DISCUSSION 
Liposomes function as drug carriers. Liposomes formation took 
place when phospholipids were dispersed in the aqueous medium 
and due to hydrophilic interaction of the lipid head groups with 
water. [28] In this study, total nine batches of liposomal acyclovir 
were prepared and each batch repeated thrice. The formulation 
contained several excipients like Lecithin, Cholesterol and 
Chloroform (solvent). Liposomal formulation of acyclovir was 
prepared by “Thin Lipid Film Method”. In this method sonication 
was a vital step for mixing up of all excipient, including the drug. 
Lecithin is a very dense excipient to be suspended properly without 
sonication. After proper mixing of all ingredients it was very 
important to dry the suspension in water bath with rotational 
movement, which would help in the formation of thin lipid film. The 
evaporation process was continued until the smell of chloroform 
was present. The freshly prepared suspensions were kept for 
overnight at 4 °C in refrigerator before any evaluation procedure. 
Drug entrapment study was performed and better entrapments 
were found from batch F2 and F9 which gave drug entrapment 
efficiency respectively about 75.49±0.51% and 73.637±9.26%. Drug 
release study of all batches was performed by using phosphate 
buffer (pH 7.4) medium. After release study it was found that 
formulation F4 showed higher percentage release (79.021 %) and F1 
showed second-highest percentage release (63.642 %) in 4 h. The 
release data was fitted to different kinetic models like Zero order, 
First order, Higuchi, Hixoncrowell and Korsmeyer-peppas. The 
highest correlation coefficients was found with zero-order model 
(r=0.9970) among all models. Hence, it may be concluded that the 
release of Acyclovir from liposomes follows zero-order kinetics and 
gave controlled drug release [29-31]. All nine batches followed zero-
order kinetics these means that they all lies under control release 
drug delivery system. According to the kinetic study F9 followed 
zero-order kinetics rather than other batches because they showed 
higher correlation coefficient compared to other formulations. That 
means these formulations followed a controlled release drug 
delivery system. From fig. 3 it is evident that F4 (Cholesterol 32.9 
mol%) showed lowest t30 value, in other words, the highest release 
rate among all other formulations. The lowest release rate 
corresponding to the highest t30 value was found from F1 formulation 
containing 66.2 mol% of cholesterol. So it may be concluded that 
rate of release of Acyclovir took place with decreasing cholesterol 
mol%. Therefore, by controlling the cholesterol mol% the rate of 
release of acyclovir may be controlled from liposomal formulations. 
From the stability study results with F4 formulation the drug 
entrapment efficiency and the release rate (exhibited by t30 value) 
changes were found after one month but those were insignificant.  
CONCLUSION 
The project was performed to exploit the activity of Acyclovir in the 
form of a liposome. Nine batches of a liposomal formulation of 
Acyclovir with varying proportions of cholesterol and lecithin were 
prepared and evaluated to estimate their entrapment efficiency, 
release rate, drug release kinetics and stability testing. Most of the 
batches were found to follow zero-order release kinetics. F3 and F9 
showed lowest and highest drug entrapment efficiencies, 
respectively with a pattern of increasing entrapment efficiency with 
decreasing proportion of cholesterol in the lipid phase. From the 
t30% drug release study it was founded that F4 gave slowest drug 
release and F9 gave the highest drug release rate. Therefore two or 
more formulations with varied release rates can be combined to 
produce a formulation with a required release rate. As F4 shows 
highest release pattern in 4 h, the stability testing of this formulation 
was carried out and the formulation was found to be stable after one 
month’s storage at 4 °C temperature. Though, long term stability 
study and clinical trial is required for future development of this 
dosage form. 
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